|1.||Pratte, Brenda: 2 articles (01/2004 - 12/2002)|
|2.||Thiel, Teresa: 2 articles (01/2004 - 12/2002)|
|3.||Zahalak, Marta: 2 articles (01/2004 - 12/2002)|
|4.||Berlinger, Balázs: 1 article (09/2015)|
|5.||Thomassen, Yngvar: 1 article (09/2015)|
|6.||Milačič, Radmila: 1 article (09/2015)|
|7.||Ščančar, Janez: 1 article (09/2015)|
|8.||Terrill, T H: 1 article (04/2015)|
|9.||Mosjidis, J A: 1 article (04/2015)|
|10.||Kegley, E B: 1 article (04/2015)|
12/01/2001 - "The efficacy of a molybdate formulation and a zinc oxide bolus as prophylactic agents for enzootic icterus was evaluated in sheep. "
12/01/2001 - "Evaluation of a commercially available molybdate formulation and zinc oxide boluses in preventing hepatic copper accumulation and thus enzootic icterus in sheep."
09/01/1975 - "Jaundice and mild hemolysis are noninterferencts and turbidity from severe lipemia is easily overcome by reversing the sequence in which reagents are added because citrate binds molybdate in preference to phosphate. "
|3.||Breast Neoplasms (Breast Cancer)
08/01/1989 - "Binding studies with 16-alpha-iodooestradiol using breast cancer tissue cytosols followed by immunoprecipitation showed activity only with oestrogen-receptor positive cytosols with optimal binding activity at 4 degrees C, unaffected by molybdate, but reduced at 25 degrees C or in the presence of 0.4 M KCl. "
12/15/1989 - "Molybdate-stabilized androgen receptors have been quantitated in cytosols derived from 1026 malignant breast tumors including all new cases of primary breast cancer reported in the western region of Norway during the 3-year period 1985-1987. "
09/15/1983 - "To further test the diversity in ER activation, DNA-cellulose binding of ER from 10 primary breast cancer tissues was determined in the presence or absence of molybdate. "
08/01/1995 - "Using MCF-7 human breast cancer cell extracts and circular permutation analysis, it was determined that molybdate-stabilized, unoccupied cytosolic ER was unable to bind to ERE-containing DNA fragments when maintained at 4 C, but that thermal activation enabled the cytosolic receptor to bind and bend ERE-containing DNA fragments to the same extent as ER present in whole cell extracts. "
01/01/1994 - "It has been shown previously that untransformed molybdate-stabilized breast cancer progesterone receptor (PR) complexes can be dissociated by KCl (0.4 to 1M) into eight different intermediate forms, or isoforms (680-600-361-224-193-119-88-52 kDa), separated by high performance size exclusion chromatography and with the use of computer assisted smoothing and deconvolution procedures (H Cren et al  J Chromatogr 615, 23-36). "
|4.||Congenital Abnormalities (Deformity)
02/01/1996 - "The mechanism by which molybdate produces joint and bone deformities is not known. "
02/01/1996 - "Therefore, the purpose of the present study was to determine the effect of molybdate on the sulfation of glycosaminoglycans (GAGS) and whether manganese-induced joint and bone deformities might be due to this mechanism. "
08/01/1965 - "The influence of copper and molybdate salts on the production of bony deformities in rats."
|5.||Photosensitivity Disorders (Photodermatitis)
|7.||tellurous acid (tellurate)
|8.||Riboflavin (Vitamin B2)